Oncology · Phase 2-3 · pulled 2026-11-06

Head and neck squamous cell carcinoma: trial sites and investigators

25 sites and 10 investigators from 274 completed and terminated Phase 2-3 trials of head and neck squamous cell carcinoma (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Head and neck squamous cell carcinoma: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	USC / Norris Comprehensive Cancer Center Los Angeles, United States · 32 spellings merged	30 16 completed, 14 terminated	NCT03645928 NCT05271604 NCT03082534 6 trials with titles NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT05271604 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2025-09-22 NCT03082534 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma completed 2025-09-11 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27 NCT05597839 Study of DF9001 in Patients With Advanced Solid Tumors completed 2025-08-15 NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors terminated 2025-05-09 Stop reason on the record: “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”	2026-02-20	23 NCT04198766 NCT06992427 NCT07276399 NCT05136196	88
2	Washington University School of Medicine St Louis, United States · 28 spellings merged	28 21 completed, 7 terminated	NCT03650764 NCT04811027 NCT04338399 6 trials with titles NCT03650764 Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma completed 2026-05-11 NCT04811027 Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC completed 2025-11-05 NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT05271604 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2025-09-22 NCT03082534 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma completed 2025-09-11	2026-05-11	34 NCT04198766 NCT06589804 NCT07276399 NCT07552558	93
3	Karmanos Cancer Institute Detroit, United States · 11 spellings merged	27 15 completed, 12 terminated	NCT06790966 NCT03355560 NCT03645928 6 trials with titles NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT03355560 Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy completed 2026-04-15 NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05	2026-08-25	12 NCT04198766 NCT07276399 NCT06385080 NCT03526835	88
4	Hospital Universitari Vall d'Hebron Barcelona, Spain · 31 spellings merged	26 14 completed, 12 terminated	NCT04868877 NCT05077709 NCT05325866 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC completed 2026-02-08 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04811027 Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC completed 2025-11-05 NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30	2026-10-01	16 NCT03526835 NCT06788990 NCT06747585 NCT06330064	81
5	University of Chicago Chicago, United States · 20 spellings merged	24 14 completed, 10 terminated	NCT05287113 NCT04428151 NCT02841748 6 trials with titles NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT02841748 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study completed 2025-10-23 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC terminated 2025-08-14 Stop reason on the record: “Interim analysis was negative” NCT04180215 A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers completed 2025-01-09	2026-06-23	19 NCT04198766 NCT06589804 NCT07276399 NCT05063552	85
6	MD Anderson Cancer Center Houston, United States · 12 spellings merged	24 12 completed, 12 terminated	NCT05325866 NCT04997902 NCT04665843 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) completed 2025-08-29 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT04180215 A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers completed 2025-01-09 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-01-28	26 NCT03556228 NCT06782555 NCT07276399 NCT05086692	87
7	University of Michigan Ann Arbor, United States · 9 spellings merged	22 16 completed, 6 terminated	NCT06790966 NCT05287113 NCT04338399 6 trials with titles NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT03082534 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma completed 2025-09-11 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT04260126 Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC completed 2025-05-14	2026-08-25	15 NCT06385080 NCT05136196 NCT06788990 NCT07195734	93
8	Gustave Roussy Villejuif, France · 16 spellings merged	22 12 completed, 10 terminated	NCT05909904 NCT05325866 NCT04428151 6 trials with titles NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04199104 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) completed 2025-03-31 NCT03212469 A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer completed 2025-02-24	2026-07-23	21 NCT07276399 NCT04892173 NCT06385080 NCT06788990	84
9	Fox Chase Cancer Center Philadelphia, United States · 3 spellings merged	21 15 completed, 6 terminated	NCT06790966 NCT05287113 NCT04338399 6 trials with titles NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT05597839 Study of DF9001 in Patients With Advanced Solid Tumors completed 2025-08-15	2026-08-25	12 NCT07276399 NCT05050162 NCT00588770 NCT04671667	92
10	Centre Léon Bérard Lyon, France · 10 spellings merged	21 15 completed, 6 terminated	NCT04338399 NCT04665843 NCT05323656 6 trials with titles NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27 NCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) completed 2025-08-21 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04199104 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) completed 2025-03-31 NCT03818061 Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck completed 2025-01-15	2025-11-02	12 NCT04892173 NCT03526835 NCT06295731 NCT06330064	89
11	Emory University Hospital Midtown Atlanta, United States · 21 spellings merged	19 13 completed, 6 terminated	NCT06790966 NCT04338399 NCT02841748 6 trials with titles NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT02841748 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study completed 2025-10-23 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC terminated 2025-08-14 Stop reason on the record: “Interim analysis was negative” NCT03754933 Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer completed 2024-12-31	2026-08-25	23 NCT04198766 NCT07276399 NCT05063552 NCT04892173	88
12	Yale University New Haven, United States · 17 spellings merged	19 10 completed, 9 terminated	NCT06790966 NCT03645928 NCT04338399 6 trials with titles NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04	2026-08-25	21 NCT07276399 NCT05063552 NCT06385080 NCT06747585	88
13	The Royal Marsden NHS Foundation Trust London, United Kingdom · 22 spellings merged	19 12 completed, 7 terminated	NCT05909904 NCT03645928 NCT04338399 6 trials with titles NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) completed 2025-08-21	2026-07-23	10 NCT07276399 NCT04892173 NCT06385080 NCT06788990	87
14	The Royal Marsden NHS Foundation Trust Sutton, United Kingdom · 22 spellings merged	19 12 completed, 7 terminated	NCT05909904 NCT04338399 NCT04428151 6 trials with titles NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27 NCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) completed 2025-08-21 NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC terminated 2025-08-14 Stop reason on the record: “Interim analysis was negative”	2026-07-23	9 NCT07276399 NCT06788990 NCT04534205 NCT06295731	87
15	Asan Medical Center Seoul, South Korea · 6 spellings merged	18 12 completed, 6 terminated	NCT05909904 NCT05287113 NCT05325866 6 trials with titles NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27	2026-07-23	8 NCT04198766 NCT07276399 NCT04892173 NCT06385080	84
16	City of Hope Duarte, United States · 10 spellings merged	18 11 completed, 7 terminated	NCT05287113 NCT05077709 NCT05325866 6 trials with titles NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC completed 2026-02-08 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04	2026-06-23	11 NCT04198766 NCT04892173 NCT07109726 NCT06295731	87
17	Dana-Farber Cancer Institute Boston, United States · 5 spellings merged	18 11 completed, 7 terminated	NCT05287113 NCT04997902 NCT02296684 6 trials with titles NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) completed 2025-08-29 NCT02296684 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma completed 2025-07-21 NCT04199104 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) completed 2025-03-31 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-06-23	18 NCT07276399 NCT06385080 NCT06788990 NCT07214987	87
18	Memorial Sloan Kettering Cancer Center New York, United States · 12 spellings merged	18 11 completed, 7 terminated	NCT03645928 NCT05271604 NCT03258554 6 trials with titles NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT05271604 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2025-09-22 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT04997902 Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) completed 2025-08-29 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT02296684 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma completed 2025-07-21	2026-02-20	18 NCT06589804 NCT03526835 NCT06788990 NCT04671667	90
19	Seoul National University Hospital Seoul, South Korea · 7 spellings merged	17 9 completed, 8 terminated	NCT04868877 NCT05909904 NCT05325866 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck completed 2025-08-27 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05	2026-10-01	10 NCT07276399 NCT06385080 NCT05086692 NCT06788990	85
20	Severance Hospital, Yonsei University Health System Seoul, South Korea · 13 spellings merged	17 11 completed, 6 terminated	NCT04868877 NCT05909904 NCT05325866 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05909904 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma completed 2026-07-23 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT05294900 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients completed 2025-10-22	2026-10-01	20 NCT04198766 NCT07276399 NCT04892173 NCT06385080	88
21	National Taiwan University Hospital Taipei, Taiwan · 8 spellings merged	17 9 completed, 8 terminated	NCT05287113 NCT04428151 NCT03358472 6 trials with titles NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) completed 2025-10-30 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04199104 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) completed 2025-03-31 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-06-23	12 NCT07276399 NCT04892173 NCT06385080 NCT06788990	85
22	Medical University of South Carolina Charleston, United States · 10 spellings merged	16 8 completed, 8 terminated	NCT03529422 NCT06790966 NCT04338399 6 trials with titles NCT03529422 Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN completed 2026-08-31 NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma terminated 2026-08-25 Stop reason on the record: “The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT05597839 Study of DF9001 in Patients With Advanced Solid Tumors completed 2025-08-15	2026-08-31	18 NCT06589804 NCT06788990 NCT07195734 NCT05050162	84
23	Moffitt Cancer Center Tampa, United States · 8 spellings merged	16 9 completed, 7 terminated	NCT05287113 NCT03645928 NCT04338399 6 trials with titles NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck completed 2026-06-23 NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-06-23	13 NCT04892173 NCT05050162 NCT04671667 NCT06332092	87
24	University of Cincinnati Medical Center Cincinnati, United States · 10 spellings merged	16 9 completed, 7 terminated	NCT03355560 NCT04313504 NCT03645928 6 trials with titles NCT03355560 Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy completed 2026-04-15 NCT04313504 Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC completed 2026-03-04 NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors terminated 2026-02-20 Stop reason on the record: “After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.” NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC completed 2025-11-02 NCT04428151 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) completed 2025-10-30 NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04	2026-04-15	16 NCT07276399 NCT04892173 NCT06788990 NCT04534205	84
25	University of Arizona Cancer Center Tucson, United States · 6 spellings merged	16 6 completed, 10 terminated	NCT03258554 NCT05814666 NCT04169074 6 trials with titles NCT03258554 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin completed 2025-09-04 NCT05814666 Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC terminated 2025-08-14 Stop reason on the record: “Interim analysis was negative” NCT04169074 Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial) terminated 2025-01-13 Stop reason on the record: “Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant immunotherapy.” NCT04459715 A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) terminated 2024-09-18 Stop reason on the record: “Study has crossed the pre-defined futility boundary at the Interim Analysis.” NCT05386550 Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) terminated 2024-08-27 Stop reason on the record: “The study was terminated by sponsor as the development program was discontinued due to outcome of phase III Trilynx study.” NCT03153982 Ruxolitinib in Operable Head and Neck Cancer terminated 2023-10-18 Stop reason on the record: “Low accrual”	2025-09-04	7 NCT07276399 NCT07195734 NCT07768189 NCT02734537	83

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Head and neck squamous cell carcinoma: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Dan P Zandberg UPMC Hillman Cancer Center	5	NCT04369937 NCT04326257 NCT04157985 NCT02777385 NCT02289209	PMID 42810217 Oral oncology, 2026 · High match PMID 42265804 Experimental hematology & oncology, 2026 · High match PMID 42102329 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 · High match
2	Douglas R Adkins Washington University School of Medicine	4	NCT03650764 NCT03655444 NCT02573493 NCT02296684	PMID 42844879 Cancer, 2026 · High match PMID 42282651 bioRxiv : the preprint server for biology, 2026 · High match PMID 41923630 Cell reports. Medicine, 2026 · High match
3	Tanguy Lim-Seiwert Johns Hopkins University	4	NCT03878979 NCT02706691 NCT03463161 NCT02551159	No paper matched at High or Medium confidence
4	Trisha Wise-Draper University of Cincinnati	3	NCT04313504 NCT03691714 NCT03355560	No paper matched at High or Medium confidence
5	Chenping Zhang the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	3	NCT05156970 NCT03370276 NCT02901483	PMID 42934376 Cellular oncology (Dordrecht, Netherlands), 2026 · High match PMID 42504531 Clinical and translational medicine, 2026 · High match PMID 42442328 EBioMedicine, 2026 · High match
6	Xingchen Peng West China Hospital	3	NCT05517330 NCT05516589 NCT05918224	PMID 42731876 Journal for immunotherapy of cancer, 2026 · High match PMID 42318476 Frontiers in oncology, 2026 · High match PMID 42189863 PLoS genetics, 2026 · High match
7	Michelle Mierzwa University of Michigan Rogel Cancer Center	3	NCT03829722 NCT03426657 NCT03386357	PMID 41343184 JAMA otolaryngology-- head & neck surgery, 2026 · High match PMID 38188292 Frontiers in oncology, 2024 · High match PMID 37162461 Cancer, 2023 · High match
8	Ezra Cohen University of California, San Diego	3	NCT03795610 NCT02644122 NCT02521870	PMID 39438862 Journal of translational medicine, 2024 · High match PMID 30386736 Frontiers in oncology, 2020 · Medium match PMID 27906454 Cancer, 2017 · High match
9	Paul Swiecicki University of Michigan Rogel Cancer Center	3	NCT03194373 NCT02762513 NCT02369458	PMID 40985049 Head & neck, 2026 · High match PMID 33989559 The Lancet. Oncology, 2021 · High match PMID 30361882 Cancer immunology, immunotherapy : CII, 2019 · High match
10	Yue He the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	2	NCT05721443 NCT05213884	PMID 42698709 Frontiers in immunology, 2026 · High match PMID 42295734 Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026 · High match PMID 42068156 IUBMB life, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.